Background: In patients with advanced fibrosis, primary end points of long-term or possibly indefinite antiviral therapy are sustained inhibition of viral replication and avoidance of emergence of resistance. In lamivudinetreated patients, the strongest predictor of emergence of YMDD mutations is baseline hepatitis B virus (HBV) DNA viral load. We aimed to verify whether abatement of viraemia by a short course of pegylated interferon (PEG-IFN-a2a) treatment before lamivudine treatment could prevent the emergence of lamivudine-associated mutations during long-term therapy. Methods: A total of 14 patients with hepatitis B e antigen (HBeAg)-negative infection (3 lamivudine-experienced and 11 lamivudine-naive), with moderate/high viraemia (>10 6 copies/ml) and with Ishak stage 4-6 at liver biopsy were sequentially treated with 180 mg PEG-IFN-a2a for a period long enough to reach HBV DNA levels ≤10 3 copies/ ml or have a decrease of 3 log 10 copies/ml from baseline. Lamivudine was then added to PEG-IFN-a2a treatment for 1 month and finally continued as monotherapy for 2 years or until viral breakthrough. Results: Baseline HBV DNA (mean ±se 2.3×10 7 ±7.2×10 7 copies/ml) decreased with PEG-IFN-a2a treatment to target value in mean ±se 3.7 ±1.3 months. None of the 11 lamivudine-naive patients developed genotypic resistance and were still HBV-DNA-negative after a mean ±se observation period of 23 ±2 months, whereas the three lamivudine-experienced patients developed YMDD mutations after 6, 9 and 12 months of lamivudine monotherapy (P=0.003, Fisher's exact test). Conclusions: In lamivudine-naive patients, abatement of HBV DNA<10 3 copies/ml by pretreatment with PEG-IFNa2a completely prevents the emergence of YMDD mutants after 24 months of lamivudine monotherapy. This sequential schedule can optimize the use of a well tolerated, effective and inexpensive drug, such as lamivudine, in highly viraemic HBV patients.
More than 350 million individuals worldwide are chronically infected with the hepatitis B virus (HBV). HBV patients are at an increased risk of developing cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC); therefore, several therapeutic protocols have been tested in the past in an attempt to prevent progression of fibrosis and to decrease the risk of HCC development. A group of patients frequently found in our epidemiological setting that require special attention are the hepatitis B e antigen (HBeAg)-negative patients with a high degree of fibrosis (Ishak stage [4] [5] [6] and high viral load (≥10 6 copies/ml): these patients require rapid and long-lasting viral suppression in order to improve their condition. The agents currently used for the treatment of chronic HBV infection can be divided into two main groups: immunomodulators (interferons [IFNs] ) and nucleoside/nucleotide analogues. Therapy with IFN is not advisable in patients with decompensated cirrhosis; however, both European [1] and Italian [2] guidelines state that it could be used in well-compensated cirrhosis. Nucleoside/nucleotide analogues can be safely used in patients with advanced disease. Lamivudine, the first oral antiviral compound available against 
Introduction
HBV infection, is an extremely useful drug because it is potent, is safe, has a very favourable cost/effect ratio, is able to induce normalization of serum alanine aminotransferase (ALT) levels, mediates the loss of HBeAg and can reduce serum HBV DNA in a high percentage of cases [3] . Its safety and efficacy were assessed in several studies and its prolonged use was shown to reduce the risk of developing HCC, especially in those who maintained an effective suppression of viral replication [4, 5] . Unfortunately, its use is associated with a high rate of emergence of the mutant YMDD (tyrosine, methionine, aspartate and aspartate) motif and other mutations of the HBV polymerase gene. The occurrence of these mutant strains is remarkably constant: after the first year of therapy, ≥20% of treated patients develop mutations. This figure progressively increases to 46% after 2 years, 56% after 3 years and >65% after 5 years [6] . With the emergence of the mutant strains, there is increasing loss of the therapeutic effects of lamivudine, with a return to high replicative levels resulting in a loss of control of inflammatory conditions in patients with chronic active hepatitis (CAH), worsening of clinical status and possible occurrence of decompensation in patients with pre-cirrhotic/cirrhotic disease [4, 6] . Baseline HBV viral load is one of the strongest predictors of emergence of mutants during lamivudine treatment in both HBeAg-positive [7] and HBeAgnegative CAH [8] . The problem of emergence of resistant strains is relevant but not disproportionated in patients with CAH, whereas it can be extremely relevant in pre-cirrhotic/cirrhotic patients in whom the primary end point of long-term inhibition of viral replication is vital in order to prevent decompensation and HCC development. This is due to the fact that the lower the HBV DNA levels, the lower the risk of both events will be [9] [10] [11] [12] . In these patients, long-term therapy should be anticipated and therefore an economical issue could arise, especially in low-income countries with highendemicity, where the most inexpensive drug could constitute a fair option.
Several strategies have been used in an attempt to control inflammatory activity by exploiting the potent and rapid antiviral action of lamivudine and overcoming the onset of mutant strains. We designed a pilot study for HBeAg-negative pre-cirrhotic/cirrhotic patients with moderate/high viral loads, in whom a sequential approach (first pegylated interferon [PEG-IFN] followed by lamivudine treatment) was used to examine whether the induction of a sharp decrease of viraemia by PEG-IFN-a2a would be able to prevent the emergence of lamivudine-associated mutations. As the rate of development of mutations with lamivudine use was constant and high, we considered it non-ethical to have a control group treated with lamivudine only.
Methods

Patients
Between May 2005 and December 2005, 14 patients with liver biopsy-proven chronic hepatitis B infection and who were HBeAg-negative were enrolled in the study according to the following criteria: Ishak stage 4-6, high viral load (HBV DNA>10 5 copies/ml), no antiviral treatment in the previous 6 months, absence of coinfection with hepatitis C virus, hepatitis delta virus or HIV, absence of decompensated cirrhosis or HCC, alcohol intake ≤40 g/day, absence of intravenous drug use in the previous 6 months and no other cause of chronic liver disease. In order to maximize the safe use of PEG-IFN-a2a, only well-compensated patients without varices, >100,000 cells/mm 3 platelets and/or >2,500 white blood cells (WBC)/mm 3 were included in the study.
Study design
The treatment schedule consisted of three consecutive phases ( Figure 1 ): phase one is the administration of PEG-IFN-a2a (Roche, Basel, Switzerland) 180 mg weekly for the period required to obtain a decrease • Check viraemia monthly • When viral load <10 3 copies/ml or decreased 3 log 10 copies/ml (if baseline was >10 8 copies/ml) proceed to phase two
• Phase three: stop pegylated interferon-α2a and continue lamivudine 100 mg/day as monotherapy for 24 months
• Check viraemia every 3 months of HBV DNA<10 3 copies/ml or a decrease of ≥3 log 10 copies/ml from baseline value in patients with baseline HBV DNA>10 8 copies/ml, phase two is a combination of PEG-IFN-a2a and lamivudine (GlaxoSmithKline, Verona, Italy) 100 mg daily for 1 month and phase three is PEG-IFN-a2a withdrawal and continuation of lamivudine 100 mg as monotherapy. Patients did not receive any other antiviral agent, corticosteroids or immunosuppressive drugs. This study was approved by the institutional review board of Azienda OspedalieroUniversitaria (Modena, Italy). All patients gave their written informed consent.
During PEG-IFN-a2a treatment, HBV DNA was quantified on a monthly basis until the target HBV DNA level was achieved. After adding lamivudine, HBV DNA was tested every 12 weeks. Viral breakthrough (VBT) was defined as a 1 log 10 copies/ml increase in serum HBV DNA over the lowest value on two successive visits.
Viral polymerase sequences were analysed at baseline, at the time of lamivudine add-on, after 1 and 2 years of lamivudine monotherapy or at the time of VBT. Serum ALT activity was determined every 4 weeks until the end of follow-up.
HBV DNA quantification and sequence analysis HBV DNA was quantified using the real-time PCR HBV PCR Kit (Abbott Laboratories, Aprilia, Italy) up to April 2007 and thereafter using the RealTime HBV DNA Assay (Abbott Laboratories), with a detection limit of 12 and 10 IU/ml, respectively. Because the conversion rate of the two methods into copies is different, results are presented as copies/ml.
The HBV polymerase sequence from amino acids 490-631 (nucleotide position 596-1016), which includes domains B and C of the viral reverse transcriptase, was analysed by direct sequencing of PCR amplicons [13] .
Statistical analyses
Quantitative parameters were expressed as mean ±se or median values and examined using a non-parametric Mann-Whitney U test. Dichotomic variables were examined using Fisher's exact test. A difference was considered to be significant at P<0.05.
Results
Baseline characteristics of patients
The baseline characteristics of patients enrolled in the sequential treatment protocol are given in Table 1 . Of a total of 14 patients, 3 (patient numbers 3, 10 and 14) had received 12 months lamivudine treatment 8-9 years prior to enrolment in the present study, Previous treatment occurred in the frame of the ZEFT01 study (Glaxo Wellcome, Verona, Italy) in which patients who were receiving standard therapy with 6 MU IFNa2b thrice weekly were randomized to receive either 12 months of lamivudine or placebo. None of these patients developed a detectable genotypic and/or phenotypic resistance at the time lamivudine treatment was stopped; therefore, they were considered eligible for the study.
Virological response
In phase one of the treatment schedule, PEG-IFN-a2a treatment alone was able to induce a sharp decrease in HBV viral load within a mean ±se of 3.7 ±1.3 months from starting PEG-IFN-a2a treatment in all but two patients (Figure 2 ; patient numbers 4 and 9). These two patients required 6 months of PEG-IFN-a2a therapy to achieve the required HBV DNA level to proceed to phase two treatment ( Figure 1) ; therefore, 12 patients were eligible to proceed to the overlap phase with lamivudine within 3 months and 2 patient within 6 months from starting PEG-IFN-a2a.
Three patients (patient numbers 3, 10 and 14) developed a virological and biochemical breakthrough after 3, 9 and 12 months of lamivudine monotherapy, respectively, whereas 11 patients maintained a complete and sustained virological control after a mean ±se of 23 ±2 months (range 21-27) after starting lamivudine monotherapy. HBV DNA level at baseline as well as mean reduction of viraemia during PEG-IFN-a2a treatment did not differ significantly between patients who developed VBT and those who did not ( Table 2 ). The only significant difference between them was that patients who developed VBT had undergone previous lamivudine therapy, whereas those who did not were lamivudine-naive (P=0.003; Table 2 ).
HBV polymerase gene sequence
At baseline, sequence analysis of the viral polymerase gene, including the B domain and the YMDD motif within the C domain, displayed wild-type sequence in all patients, including the three patients who had previously been treated with lamivudine (all in association with IFN-a). Indeed, none of them had developed VBT or clinically relevant resistance while on therapy, which was stopped in accordance to the study protocol duration. Table 2 . Virological characteristic of patients according to occurrence or non-occurrence of virological breakthrough
For patients developing viral breakthrough (VBT), the viral load at the time of its occurrence was considered. CI, confidence interval; PEG-IFN-a2a, pegylated interferon-a2a.
Sequence analysis at the time of VBT in these three patients showed occurrence of mutation in all at position 204 (patient number 3 developed M204V and patient numbers 10 and 14 developed M204I).
Biochemical response
ALT levels paralleled the decrease of HBV DNA levels with return to normal values in close proximity of achieving an HBV-DNA-negative status. In the three patients who developed VBT, ALT levels increased slightly without worsening of liver function or development of clinical decompensation (Table 3) .
Adverse events
PEG-IFN-a2a treatment was well tolerated in all in patients, including those with established cirrhosis. Platelet count decreased during PEG-IFN-a2a treatment by approximately 30%; there was no need to stop therapy in any of the patients. Dose reduction from 180 to 135 mg was necessary in only one patient after 1 month of therapy because of a marked decrease of WBC count. Granulocyte colony-stimulating factor was transiently used in two other patients without the need of a dose reduction. Lamivudine treatment was well tolerated in all patients.
Discussion
Several strategies have been used in an attempt to control inflammatory activity and to overcome the onset of mutant strains during lamivudine monotherapy. Most studies evaluated the combination of lamivudine and PEG-IFN-a2a as simultaneous combination or as sequential administration. Although some slight differences were present between different sequential protocols as far as dosage of the two drugs and timing of the addition of PEG-IFN-a2a to lamivudine treatment were concerned, such studies were similar in principle and always consisted of lamivudine followed by PEG-IFN-a2a after several weeks [14] [15] [16] [17] [18] [19] . Overall, sequential treatment attained only a moderate increase of sustained virological response compared with simultaneous lamivudine and PEG-IFN-a2a administration protocols with a percentage of emergence of YMDD mutants that was only slightly lower compared with that occurring with monotherapy [20] .
The recently published guidelines on treatment of HBV do not recommend the use of lamivudine in treatment-naive patients because of the high probability in developing resistant mutants, especially in patients with high HBV DNA levels [1, 2, 21] . Indeed, it is well known that the occurrence of lamivudine resistance caused by mutations in the polymerase region is extremely frequent during the first year of treatment with lamivudine both in HBeAg-positive patients [7] as well as in HBeAg-negative patients [8] , and pretreatment HBV viral load is one of the strongest predictors for emergence of lamivudine resistance.
In the participants of this study, (that is, patients with advanced, although compensated, disease [Ishak stage [4] [5] [6] with moderate/high viral load [mean ±se 2.3×10 7 ±1.9×10 7 copies/ml]), a sustained inhibition of viral replication was needed to prevent the risks associated with persistent replication, both in terms of decompensation [4] [5] [6] [7] [8] and the development of HCC [9] [10] [11] [12] . As therapy with oral antiviral drugs in these patients should be continued indefinitely, unless hepatitis B surface antigen/ anti-hepatitis B surface antigen seroconversion occurs, the issue of cost is highly relevant and the more convenient drug in terms of cost/ effectiveness should be used. The cost for 1 year of therapy with lamivudine is approximately one-sixth of that with any other antiviral oral drug available at present. Moreover, as far as the bulk of literature on antiviral drugs is concerned, lamivudine is by far the most well known and safest available drug. The short period of PEG-IFN-a2a treatment in preparation for lamivudine does not add much in terms of costs and side effects, even for patients with advanced disease (that is, patients with Ishak stage ≥4) provided they are well-compensated. For patients developing viral breakthrough (VBT), the end of follow-up was considered when VBT occurred. ALT, alanine aminotransferase; CI, confidence interval; PEG-IFN-a2a, pegylated interferon-a2a.
The strength of the present protocol resides on the evidence that abatement of HBV viral load by PEG-IFNa2a treatment before the use of lamivudine in monotherapy is able to effectively suppress viral replication and prevent the onset of lamivudine-associated resistance in highly viraemic patients with HBeAg-negative pre-cirrhotic/cirrhotic liver disease. Indeed, all treated patients rapidly reached and maintained virological suppression (HBV DNA<10-12 IU/ml) during phase three of the protocol (that is, during lamivudine monotherapy. In addition, none of the treatment-naive patients developed resistance to lamivudine after 2 years in comparison with the expected 20% at 1 year and 46% at 2 years [6, 20] . To reach complete success with the sequential use of PEG-IFN-a2a plus lamivudine, it is mandatory that the patients are lamivudine-naive as previous exposure to lamivudine hampers the beneficial effect of the sequential protocol, even in the absence of detectable mutations at enrolment. The rapid development of lamivudine resistance in lamivudine-experienced patients, even if the previous exposure to lamivudine had been short (1 year), occurred >8 years earlier and was not accompanied by virological or biochemical breakthrough. This suggests that during the previous lamivudine course, a minimal population of mutated viruses developed but did not reach detectability as the length of treatment was short. Mutations, however, had been archived and promptly became the dominant population under lamivudine rechallenge [22] .
Although this is a small study, the results of sequential protocol are an important proof of concept that abatement of HBV viral load with a short pretreatment with PEG-IFN-a2a is sufficient to abolish the emergence of YMDD mutants during 24 months of lamivudine monotherapy. This sequential schedule, if applied in highly viraemic pre-cirrhotic/cirrhotic HBV patients, can make the best use of an extremely well tolerated, safe, effective and inexpensive drug such as lamivudine. In patients who are unable to tolerate PEG-IFN-a2a treatment or with more decompensated disease, a reduction of viral replication could be achieved with a potent drug that has a high genetic barrier before carrying on indefinitely with lamivudine. Furthermore, the approach of reducing the viral load by pretreatment with PEG-IFN-a2a can also be suggested as a general line of attack before administration of other nucleoside/nucleotide analogues that have a low genetic barrier in order to optimize their performance.
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